$TVTX
Travere Therapeutics Inc Stock $tvtx

$tvtx Overview Financials Valuation SEC Filings Company Website

2019 Q4 Form 10-Q Financial Statement

#000143853319000036 Filed on October 30, 2019

Income Statement

Concept	2019 Q4	2019 Q3	2018 Q4
Revenue	$46.69M	$44.37M	$43.77M
YoY Change	6.66%	9.01%	104116.67%
Cost Of Revenue	$1.730M	$1.513M	$1.600M
YoY Change	8.13%	33.54%	36.75%
Gross Profit	$44.96M	$42.86M	$42.17M
YoY Change	6.62%	8.31%	2.85%
Gross Profit Margin	96.3%	96.59%	96.34%
Selling, General & Admin	$22.71M	$29.78M	$21.54M
YoY Change	5.43%	14.07%	-3.84%
% of Gross Profit	50.51%	69.48%	51.08%
Research & Development	$36.07M	$33.22M	$31.70M
YoY Change	13.79%	2.38%	62.65%
% of Gross Profit	80.23%	77.51%	75.17%
Depreciation & Amortization	$5.290M	$5.380M	$4.880M
YoY Change	8.4%	12.08%	9.42%
% of Gross Profit	11.77%	12.55%	11.57%
Operating Expenses	$63.90M	$78.81M	$48.76M
YoY Change	31.06%	3.3%	-14.99%
Operating Profit	-$28.17M	-$34.44M	-$4.985M
YoY Change	465.04%	-3.22%	-67.15%
Interest Expense	-$11.65M	-$4.547M	-$2.370M
YoY Change	391.56%	79.51%	-43.97%
% of Operating Profit
Other Income/Expense, Net	-$2.060M	-$2.576M	-$2.470M
YoY Change	-16.6%	-86.09%	-159.68%
Pretax Income	-$30.23M	-$37.01M	-$7.455M
YoY Change	305.46%	-31.59%	-32.46%
Income Tax	$32.00K	-$523.0K	$0.00
% Of Pretax Income
Net Earnings	-$30.26M	-$36.49M	-$7.455M
YoY Change	305.89%	-33.07%	-57.69%
Net Earnings / Revenue	-64.81%	-82.23%	-17.03%
Basic Earnings Per Share			-$0.18
Diluted Earnings Per Share	-$703.2K	-$849.8K	-$0.18
COMMON SHARES
Basic Shares Outstanding	42.96M shares	42.95M shares	41.25M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q4	2019 Q3	2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$271.9M	$296.1M	$311.3M
YoY Change	-12.66%	-15.61%	39.83%
Cash & Equivalents	$62.44M	$65.19M	$102.9M
Short-Term Investments	$209.5M	$230.9M	$208.5M
Other Short-Term Assets	$6.400M	$10.60M	$5.900M
YoY Change	8.47%	89.29%	-1.67%
Inventory	$6.082M	$5.264M	$5.619M
Prepaid Expenses
Receivables	$18.05M	$16.80M	$12.66M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$429.1M	$439.7M	$495.7M
YoY Change	-13.44%	-12.58%	52.14%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.891M	$2.910M	$3.146M
YoY Change	-8.11%	-12.43%	-2.6%
Goodwill	$936.0K	$936.0K	$936.0K
YoY Change	0.0%	0.0%	0.0%
Intangibles	$157.2M		$186.7M
YoY Change	-15.8%		1.01%
Long-Term Investments	$0.00	$0.00	$15.00M
YoY Change	-100.0%	-100.0%
Other Assets	$14.71M	$12.45M	$7.709M
YoY Change	90.8%	68.44%	38.75%
Total Long-Term Assets	$175.7M	$174.1M	$213.5M
YoY Change	-17.68%	-18.34%	9.74%
TOTAL ASSETS
Total Short-Term Assets	$429.1M	$439.7M	$495.7M
Total Long-Term Assets	$175.7M	$174.1M	$213.5M
Total Assets	$604.8M	$613.8M	$709.2M
YoY Change	-14.72%	-14.29%	36.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$26.61M	$13.83M	$6.954M
YoY Change	282.71%	48.51%	-63.28%
Accrued Expenses	$51.75M	$47.87M	$49.70M
YoY Change	4.13%	10.44%	37.97%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00	$22.50M
YoY Change	-100.0%	-100.0%
Total Short-Term Liabilities	$95.45M	$88.02M	$104.6M
YoY Change	-8.77%	-11.87%	22.12%
LONG-TERM LIABILITIES
Long-Term Debt	$204.9M	$202.4M	$195.1M
YoY Change	5.02%	4.98%	332.59%
Other Long-Term Liabilities	$20.89M	$21.49M	$17.55M
YoY Change	19.09%	339.86%	609.75%
Total Long-Term Liabilities	$20.89M	$21.49M	$17.55M
YoY Change	19.09%	339.86%	609.75%
TOTAL LIABILITIES
Total Short-Term Liabilities	$95.45M	$88.02M	$104.6M
Total Long-Term Liabilities	$20.89M	$21.49M	$17.55M
Total Liabilities	$383.6M	$367.9M	$390.9M
YoY Change	-1.87%	-7.37%	72.05%
SHAREHOLDERS EQUITY
Retained Earnings	-$416.4M	-$386.2M	-$270.0M
YoY Change	54.23%	47.08%	51.99%
Common Stock	$636.9M	$631.0M	$589.8M
YoY Change	7.99%	8.28%	25.01%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$221.2M	$246.0M	$318.3M
YoY Change
Total Liabilities & Shareholders Equity	$604.8M	$613.8M	$709.2M
YoY Change	-14.72%	-14.29%	36.29%

Cashflow Statement

Concept	2019 Q4	2019 Q3	2018 Q4
OPERATING ACTIVITIES
Net Income	-$30.26M	-$36.49M	-$7.455M
YoY Change	305.89%	-33.07%	-57.69%
Depreciation, Depletion And Amortization	$5.290M	$5.380M	$4.880M
YoY Change	8.4%	12.08%	9.42%
Cash From Operating Activities	-$4.490M	-$14.12M	-$3.570M
YoY Change	25.77%	262.05%	315.12%
INVESTING ACTIVITIES
Capital Expenditures	-$3.980M	-$4.220M	-$3.860M
YoY Change	3.11%	9.61%	31.29%
Acquisitions
YoY Change
Other Investing Activities	$5.560M	$8.680M	-$44.94M
YoY Change	-112.37%	-105.5%	-1682.39%
Cash From Investing Activities	$1.580M	$4.460M	-$48.80M
YoY Change	-103.24%	-102.76%	44263.64%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	90.00K	-740.0K	520.0K
YoY Change	-82.69%	-100.32%	-62.04%
NET CHANGE
Cash From Operating Activities	-4.490M	-14.12M	-3.570M
Cash From Investing Activities	1.580M	4.460M	-48.80M
Cash From Financing Activities	90.00K	-740.0K	520.0K
Net Change In Cash	-2.820M	-10.40M	-51.85M
YoY Change	-94.56%	-115.88%	-13062.5%
FREE CASH FLOW
Cash From Operating Activities	-$4.490M	-$14.12M	-$3.570M
Capital Expenditures	-$3.980M	-$4.220M	-$3.860M
Free Cash Flow	-$510.0K	-$9.900M	$290.0K
YoY Change	-275.86%	19700.0%	-86.06%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
	dei	Entity Central Index Key EntityCentralIndexKey	0001438533
CY2018Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0	shares
CY2019Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0	shares
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2019Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41389524	shares
CY2019Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	42958401	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41389524	shares
CY2019Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	42958401	shares
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2019Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2019Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2019-09-30
	dei	City Area Code CityAreaCode	888
	dei	Entity Registrant Name EntityRegistrantName	RETROPHIN, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-4842691
	dei	Entity Address Address Line1 EntityAddressAddressLine1	3721 Valley Centre Drive
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 200
	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-36257
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92130
CY2019Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	16781000	USD
	dei	Local Phone Number LocalPhoneNumber	969-7879
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	RTRX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2019Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	42958401	shares
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	65188000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	102873000	USD
CY2019Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	341835000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	368668000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	12662000	USD
CY2019Q3	us-gaap	Inventory Net InventoryNet	5264000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	5619000	USD
CY2019Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8628000	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4140000	USD
CY2019Q3	us-gaap	Prepaid Taxes PrepaidTaxes	2022000	USD
CY2018Q4	us-gaap	Prepaid Taxes PrepaidTaxes	1716000	USD
CY2019Q3	us-gaap	Assets Current AssetsCurrent	439718000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	495678000	USD
CY2019Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2910000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3146000	USD
CY2019Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	12453000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	7709000	USD
CY2019Q3	us-gaap	Equity Method Investments EquityMethodInvestments	0	USD
CY2018Q4	us-gaap	Equity Method Investments EquityMethodInvestments	15000000	USD
CY2019Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	157799000	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	186691000	USD
CY2019Q3	us-gaap	Goodwill Goodwill	936000	USD
CY2018Q4	us-gaap	Goodwill Goodwill	936000	USD
CY2019Q3	us-gaap	Assets Assets	613816000	USD
CY2018Q4	us-gaap	Assets Assets	709160000	USD
CY2019Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	13832000	USD
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	32448000	USD
CY2019Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	8411000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	390907000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6954000	USD
CY2019Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	47874000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	49695000	USD
CY2018Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	6165000	USD
CY2019Q3	rtrx	Acquisition Related Contingent Consideration AcquisitionRelatedContingentConsideration	17900000	USD
CY2018Q4	rtrx	Acquisition Related Contingent Consideration AcquisitionRelatedContingentConsideration	19350000	USD
CY2019Q3	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	0	USD
CY2018Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	22457000	USD
CY2019Q3	us-gaap	Liabilities Current LiabilitiesCurrent	88017000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	104621000	USD
CY2019Q3	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	202355000	USD
CY2018Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	195091000	USD
CY2019Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	21487000	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	17545000	USD
CY2019Q3	rtrx	Acquisition Related Contingent Consideration Noncurrent AcquisitionRelatedContingentConsiderationNoncurrent	56000000	USD
CY2018Q4	rtrx	Acquisition Related Contingent Consideration Noncurrent AcquisitionRelatedContingentConsiderationNoncurrent	73650000	USD
CY2019Q3	us-gaap	Liabilities Liabilities	367859000	USD
CY2019Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q3	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2019Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	630966000	USD
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	589795000	USD
CY2019Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-386185000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-270017000	USD
CY2019Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1172000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1529000	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	245957000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	318253000	USD
CY2019Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	613816000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	709160000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	44373000	USD
CY2018Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	40706000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	128651000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	120475000	USD
CY2019Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1513000	USD
CY2018Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1133000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3509000	USD
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	25500000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3924000	USD
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	33220000	USD
CY2019Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	29779000	USD
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2019Q3	rtrx	Write Off Of Contingent Consideration WriteOffOfContingentConsideration	0	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	104597000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	91544000	USD
CY2018Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	26107000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	101418000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	77675000	USD
CY2019Q3	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	-702000	USD
CY2018Q3	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	16601000	USD
	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	5820000	USD
	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	22387000	USD
CY2019Q3	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2018Q3	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2018Q3	rtrx	Write Off Of Contingent Consideration WriteOffOfContingentConsideration	0	USD
	rtrx	Write Off Of Contingent Consideration WriteOffOfContingentConsideration	18000000	USD
	rtrx	Write Off Of Contingent Consideration WriteOffOfContingentConsideration	0	USD
CY2019Q3	us-gaap	Impairment Of Retained Interest ImpairmentOfRetainedInterest	15000000	USD
CY2018Q3	us-gaap	Impairment Of Retained Interest ImpairmentOfRetainedInterest	0	USD
	us-gaap	Impairment Of Retained Interest ImpairmentOfRetainedInterest	15000000	USD
	us-gaap	Impairment Of Retained Interest ImpairmentOfRetainedInterest	0	USD
CY2019Q3	us-gaap	Operating Expenses OperatingExpenses	78810000	USD
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	76289000	USD
	us-gaap	Operating Expenses OperatingExpenses	237844000	USD
	us-gaap	Operating Expenses OperatingExpenses	195530000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-34437000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-35583000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-109193000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-75055000	USD
CY2019Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-496000	USD
CY2018Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-90000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-673000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-372000	USD
CY2019Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	2467000	USD
CY2018Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	1147000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	7875000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	2905000	USD
CY2019Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-4547000	USD
CY2018Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-2533000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-14230000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-4848000	USD
CY2019Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2018Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-17042000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-17042000	USD
CY2019Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2576000	USD
CY2018Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-18518000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-7028000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-19357000	USD
CY2019Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-37013000	USD
CY2018Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-54101000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-116221000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-94412000	USD
CY2019Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-523000	USD
CY2018Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	415000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-53000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	811000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-36490000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-54516000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-116168000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-95223000	USD
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.85
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.34
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.76
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.37
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	42943828	shares
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	40717440	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	42109618	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	40149184	shares
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-36490000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-54516000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-116168000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-95223000	USD
CY2019Q3	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	315000	USD
CY2018Q3	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	5000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	342000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	29000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	75000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	64000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	2359000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-97000	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-36100000	USD
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-54447000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-113467000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-95291000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-116168000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-95223000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	15118000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	13789000	USD
	rtrx	Noncash Interest Expense NoncashInterestExpense	1134000	USD
	rtrx	Noncash Interest Expense NoncashInterestExpense	1115000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	779000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-749000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	7397000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	980000	USD
	rtrx	Provision For Inventory ProvisionForInventory	-646000	USD
	rtrx	Provision For Inventory ProvisionForInventory	1625000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	16608000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	14920000	USD
	rtrx	Net Changein Fair Valueof Contingent Consideration NetChangeinFairValueofContingentConsideration	-12180000	USD
	rtrx	Net Changein Fair Valueof Contingent Consideration NetChangeinFairValueofContingentConsideration	22387000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-4329000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-6852000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-17042000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	25500000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
	us-gaap	Impairment Of Retained Interest ImpairmentOfRetainedInterest	15000000	USD
	us-gaap	Impairment Of Retained Interest ImpairmentOfRetainedInterest	0	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-539000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-270000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-15000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	15000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3989000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1346000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-947000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1428000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	9629000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	2183000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	4962000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	6991000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	6778000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	3094000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-53722000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21393000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	286000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	727000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	11299000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	15108000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	180818000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	96166000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	150950000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	219820000	USD
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	0	USD
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	15000000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	18283000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-154489000	USD
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	2562000	USD
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	8842000	USD
	rtrx	Payment Of Guaranteed Minimum Royalty PaymentOfGuaranteedMinimumRoyalty	1559000	USD
	rtrx	Payment Of Guaranteed Minimum Royalty PaymentOfGuaranteedMinimumRoyalty	1500000	USD
	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	0	USD
	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	750000	USD
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	USD
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	4274000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	944000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	10379000	USD
	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	0	USD
	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	276000000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	40203000	USD
	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	0	USD
	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	8820000	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	1005000	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	800000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2172000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	231338000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-74000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-30000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-37685000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	55426000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	102873000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	99394000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	65188000	USD
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	154820000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	277089000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	287989000	USD
CY2019Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	4178000	USD
CY2018Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	4801000	USD
CY2019Q3	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	627000	USD
CY2018Q3	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	3489000	USD
CY2018Q3	rtrx	Exercise Of Warrants And Reclassification Of Derivative Liability ExerciseOfWarrantsAndReclassificationOfDerivativeLiability	2134000	USD
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	74945000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	76000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	64000	USD
CY2019Q3	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	315000	USD
CY2018Q3	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	5000	USD
CY2018Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	74945000	USD
CY2019Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	162000	USD
CY2018Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	154000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-36490000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-54516000	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	245957000	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	319065000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	318253000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	293134000	USD
CY2018Q1	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	15710000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	16125000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	14716000	USD
	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	944000	USD
	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	10379000	USD
	rtrx	Exercise Of Warrants And Reclassification Of Derivative Liability ExerciseOfWarrantsAndReclassificationOfDerivativeLiability	4274000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	2359000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-97000	USD
	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	342000	USD
	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	29000	USD
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	22590000	USD
CY2019Q3	rtrx	Debt Securities Availableforsale Amortized Cost Basis Noncurrent DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent	110393000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1512000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1198000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-116168000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-95223000	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	245957000	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	319065000	USD
	us-gaap	Nature Of Operations NatureOfOperations	DESCRIPTION OF BUSINESS<div style="line-height:120%;padding-bottom:8px;padding-top:16px;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;color:#006ebf;font-style:normal;font-weight:bold;text-decoration:none;">Organization and Description of Business</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Retrophin, Inc. (“we”, “our”, “us”, “Retrophin” and the “Company”) refers to Retrophin, Inc., a Delaware corporation, as well as our direct and indirect subsidiaries. Retrophin is a biopharmaceutical company headquartered in San Diego, California, focused on identifying, developing and delivering life-changing therapies to people living with rare diseases. We regularly evaluate and, where appropriate, act on opportunities to expand our product pipeline through licenses and acquisitions of products in areas that will serve patients with rare diseases and that we believe offer attractive growth characteristics.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"><span style="font-family:Arial;font-size:10.5pt;color:#666666;font-style:italic;font-weight:bold;text-decoration:none;">Product Candidate Development Activities:</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Sparsentan</span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;">,</span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> also known as RE-021, is an investigational product candidate with a dual mechanism of action, a potent angiotensin receptor blocker (“ARB”) and selective endothelin receptor antagonist (“ERA”), with in vitro selectivity toward endothelin receptor type A. Sparsentan is currently being evaluated in two pivotal Phase 3 clinical studies in the following indications:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#4c4c4c;font-weight:bold;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9.5pt;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Focal segmental glomerulosclerosis ("FSGS") is a rare kidney disease characterized by proteinuria where the glomeruli become progressively scarred. FSGS is a leading cause of end-stage renal disease.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#4c4c4c;font-weight:bold;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9.5pt;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Immunoglobulin A nephropathy ("IgAN") is an immune-complex-mediated glomerulonephritis characterized by hematuria, proteinuria, and variable rates of progressive renal failure. IgAN is the most common primary glomerular disease.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:12px;text-align:justify;font-size:10.5pt;"><span style="font-family:Arial;font-size:10.5pt;color:#666666;font-style:italic;font-weight:bold;text-decoration:none;">The Company has three approved products:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Chenodal (chenodiol tablets) is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has been the standard of care for cerebrotendinous xanthomatosis ("CTX") patients for more than three decades and the Company is currently pursuing adding this indication to the label.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Cholbam (cholic acid capsules) is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Thiola (tiopronin tablets) is approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria. On June 28, 2019, the Company </span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">announced that the U.S. Food and Drug Administration ("FDA") approved 100 mg and 300 mg tablets of THIOLA EC</span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">™</span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> (tiopronin), a new enteric-coated formulation of THIOLA® (tiopronin), to be used for the treatment of cystinuria.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"><span style="font-family:Arial;font-size:10.5pt;color:#666666;font-style:italic;font-weight:bold;text-decoration:none;">Cooperative Research and Development Agreements ("CRADAs"):</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The Company is a participant in two CRADAs, which form a multi-stakeholder approach to pool resources with leading experts, and incorporates the patient perspective early in the identification and development process. Retrophi</span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">n has partnered with the </span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">National Institutes of Health’s National Center for Advancing Translational Sciences ("NCATS")</span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> and leading patients advocacy organization, NGLY1.org and </span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Alagille Syndrome Alliance ("ALGSA")</span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, aimed at the identification of potential small molecule therapeutics for NGLY1 deficiency, and Alagille syndrome respectively, diseases with no approved treatment options.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"><span style="font-family:Arial;font-size:10.5pt;color:#666666;font-style:italic;font-weight:bold;text-decoration:none;">Changes in Development Activities:</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">In August 2019, the Company announced that the Phase 3 FORT Study evaluating the safety and efficacy of fosmetpantotenate compared to placebo in patients with pantothenate kinase-associated neurodegeneration ("PKAN") did not meet its primary endpoint and did not demonstrate a difference between treatment groups. The study also did not meet its secondary endpoint. The Company will not proceed with further development of fosmetpantotenate for PKAN.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">In August 2019, following a strategic review of the CNSA-001 program in patients with phenylketonuria ("PKU"), the Company made the decision to decline to exercise its option to acquire Censa Pharmaceuticals and accordingly discontinue its joint development program for CNSA-001.</span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> The Company impaired the related </span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"><span>$15 million</span></span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> long term investment during the third quarter of 2019.</span></div><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">During the first quarter of 2019, the Company elected to discontinue development of the L-UDCA program, resulting in impairment of the intangible asset of </span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"><span>$25.5 million</span></span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, originally recorded in 2016, and the related </span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"><span>$18.0 million</span></span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> in contingent liability. This resulted in a net </span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"><span>$7.5 million</span></span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> non-cash charge to first quarter operations. In June 2016, the Company acquired certain rights to its product candidate L-UDCA for </span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"><span>$0.5 million</span></span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> cash. At the same time the Company established a related non-cash asset of </span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"><span>$25.5 million</span></span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> and liability of </span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"><span>$25.0 million</span></span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> for IPR&D and contingent consideration (deferred financing) related net sales royalties and milestones. As a result of our quarterly valuation update process during 2016 and 2017, the contingent liability was decreased by </span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"><span>$2.3 million</span></span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> and </span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"><span>$5.7 million</span></span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, respectively, and increased by </span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"><span>$1.0 million</span></span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> during 2018. The resulting balance of the L-UDCA contingent liability at December 31, 2018 was </span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"><span>$18.0 million</span></span>.
CY2019Q3	us-gaap	Impairment Of Retained Interest ImpairmentOfRetainedInterest	15000000	USD
CY2019Q1	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-7500000	USD
CY2016Q2	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	500000	USD
CY2016Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	25000000.0	USD
CY2016	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-2300000	USD
CY2017	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-5700000	USD
CY2018	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1000000.0	USD
CY2019Q3	rtrx	Debt Securities Available For Sale Unrealized Gain Noncurrent DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent	598000	USD
CY2019Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	341800000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	44373000	USD
CY2018Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	40706000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	128651000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	120475000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	180800000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	151000000.0	USD
CY2019Q3	us-gaap	Marketable Securities MarketableSecurities	341835000	USD
CY2018Q4	us-gaap	Marketable Securities MarketableSecurities	368668000	USD
CY2019Q3	rtrx	Debt Securities Availableforsale Amortized Cost Basis Current DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent	230364000	USD
CY2019Q3	rtrx	Debt Securities Available For Sale Unrealized Gain Current DebtSecuritiesAvailableForSaleUnrealizedGainCurrent	565000	USD
CY2019Q3	rtrx	Debt Securities Available For Sale Unrealized Loss Current DebtSecuritiesAvailableForSaleUnrealizedLossCurrent	18000	USD
CY2019Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	230911000	USD
CY2018Q4	rtrx	Debt Securities Available For Sale Unrealized Gain Noncurrent DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent	22000	USD
CY2018Q4	rtrx	Debt Securities Available For Sale Unrealized Loss Noncurrent DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent	639000	USD
CY2019Q3	rtrx	Debt Securities Available For Sale Unrealized Loss Noncurrent DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent	67000	USD
CY2019Q3	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	110924000	USD
CY2019Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	340757000	USD
CY2019Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1163000	USD
CY2019Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	85000	USD
CY2019Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	341835000	USD
CY2018Q4	rtrx	Debt Securities Availableforsale Amortized Cost Basis Current DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent	209137000	USD
CY2018Q4	rtrx	Debt Securities Available For Sale Unrealized Gain Current DebtSecuritiesAvailableForSaleUnrealizedGainCurrent	0	USD
CY2018Q4	rtrx	Debt Securities Available For Sale Unrealized Loss Current DebtSecuritiesAvailableForSaleUnrealizedLossCurrent	662000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	208475000	USD
CY2018Q4	rtrx	Debt Securities Availableforsale Amortized Cost Basis Noncurrent DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent	160810000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	160193000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	369947000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	22000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1301000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	368668000	USD
CY2019Q2	us-gaap	Cost Method Investments CostMethodInvestments	15000000.0	USD
CY2018Q1	rtrx	Business Combination Option Agreement Purchase Price BusinessCombinationOptionAgreementPurchasePrice	65000000.0	USD
CY2018Q1	rtrx	Business Combination Option Agreement Purchase Price Percent Transferred In Cash BusinessCombinationOptionAgreementPurchasePricePercentTransferredInCash	0.20
CY2018Q1	rtrx	Business Combination Option Agreement Purchase Price Percent Transferred By Issuance Of Equity BusinessCombinationOptionAgreementPurchasePricePercentTransferredByIssuanceOfEquity	0.80
CY2018Q1	rtrx	Business Combination Option Agreement Share Price BusinessCombinationOptionAgreementSharePrice	21.40
CY2018Q1	rtrx	Business Combination Option Agreement Percent Of Consideration Paid In Cash If Share Price Falls Below Share Price Threshold BusinessCombinationOptionAgreementPercentOfConsiderationPaidInCashIfSharePriceFallsBelowSharePriceThreshold	1
CY2018Q1	rtrx	Business Combination Option Agreement Contingent Consideration BusinessCombinationOptionAgreementContingentConsideration	25000000.0	USD
CY2019Q3	us-gaap	Impairment Of Retained Interest ImpairmentOfRetainedInterest	15000000	USD
CY2016Q3	rtrx	Lessee Operating Lease Square Footage Leased LesseeOperatingLeaseSquareFootageLeased	45000	sqft
CY2016Q3	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P7Y7M
CY2016Q3	rtrx	Operating Lease Incentive Tenant Improvements OperatingLeaseIncentiveTenantImprovements	2300000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	787000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2958000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2486000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2560000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	2637000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	1585000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	14000000.0	USD
CY2019Q1	rtrx	Operating Lease Incentive Tenant Improvements OperatingLeaseIncentiveTenantImprovements	1800000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.077
CY2019Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y7M
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7900000	USD
CY2019Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	11300000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	13013000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2538000	USD
CY2019Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	10475000	USD
CY2019Q3	rtrx	Operating Lease Incentive Tenant Improvements OperatingLeaseIncentiveTenantImprovements	1543000	USD
CY2019Q3	rtrx	Straight Line Lease Expense In Excess Of Cash Payments StraightLineLeaseExpenseInExcessOfCashPayments	1585000	USD
CY2019Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7347000	USD
CY2019Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7347000	USD
CY2019Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2668000	USD
CY2019Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7807000	USD
CY2019Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	10475000	USD
CY2019Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	700000	USD
	us-gaap	Operating Lease Expense OperatingLeaseExpense	2000000.0	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	65188000	USD
CY2019Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	341835000	USD
CY2019Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	407023000	USD
CY2019Q3	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	73900000	USD
CY2019Q3	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	73900000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	102873000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	368668000	USD
CY2018Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	471541000	USD
CY2018Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	93000000	USD
CY2018Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	93000000	USD
	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	5820000	USD
CY2019Q3	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	-700000	USD
	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	5800000	USD
	rtrx	Write Off Of Contingent Consideration WriteOffOfContingentConsideration	18000000.0	USD
CY2018Q3	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	16600000	USD
	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	22400000	USD
CY2019Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	157800000	USD
CY2019Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	241195000	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	255643000	USD
CY2019Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	83396000	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	68952000	USD
CY2019Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	157799000	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	186691000	USD
CY2019Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5007000	USD
CY2018Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4625000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	14594000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	13319000	USD
CY2019Q3	us-gaap	Debt Instrument Repurchase Amount DebtInstrumentRepurchaseAmount	23400000	USD
CY2019Q2	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	1300000	shares
CY2019Q3	rtrx	Government Rebates Payable GovernmentRebatesPayable	5934000	USD
CY2018Q4	rtrx	Government Rebates Payable GovernmentRebatesPayable	8464000	USD
CY2019Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	13490000	USD
CY2018Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	10446000	USD
CY2019Q3	rtrx	Accrued Royaltyand Contingent Consideration AccruedRoyaltyandContingentConsideration	6888000	USD
CY2018Q4	rtrx	Accrued Royaltyand Contingent Consideration AccruedRoyaltyandContingentConsideration	6805000	USD
CY2019Q3	rtrx	Accrued Liabilities Researchand Development Current AccruedLiabilitiesResearchandDevelopmentCurrent	16300000	USD
CY2018Q4	rtrx	Accrued Liabilities Researchand Development Current AccruedLiabilitiesResearchandDevelopmentCurrent	16515000	USD
CY2019Q3	rtrx	Accrued Liabilities Selling Generaland Administrative Current AccruedLiabilitiesSellingGeneralandAdministrativeCurrent	3593000	USD
CY2018Q4	rtrx	Accrued Liabilities Selling Generaland Administrative Current AccruedLiabilitiesSellingGeneralandAdministrativeCurrent	2990000	USD
CY2019Q3	rtrx	Accrued Liabilities Miscellaneous AccruedLiabilitiesMiscellaneous	1669000	USD
CY2018Q4	rtrx	Accrued Liabilities Miscellaneous AccruedLiabilitiesMiscellaneous	4475000	USD
CY2019Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	47874000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	49695000	USD
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	42943828	shares
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-36490000	USD
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.85
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	40717440	shares
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-54516000	USD
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.34
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	42109618	shares
	us-gaap	Net Income Loss NetIncomeLoss	-116168000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.76
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	40149184	shares
	us-gaap	Net Income Loss NetIncomeLoss	-95223000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.37
CY2019Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15449000	shares
CY2018Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16318000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16218000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16325000	shares
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4900000	shares
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	18.80
CY2019Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4340000	USD
CY2018Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4885000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	16608000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14920000	USD
CY2018Q3	rtrx	Classof Warrantor Right Common Stock Issued Upon Exerciseof Warrants ClassofWarrantorRightCommonStockIssuedUponExerciseofWarrants	532830	shares
	rtrx	Classof Warrantor Right Common Stock Issued Upon Exerciseof Warrants ClassofWarrantorRightCommonStockIssuedUponExerciseofWarrants	956887	shares
CY2018Q3	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2100000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	4300000	USD
CY2019Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.014
CY2018Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.008
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.009
CY2019Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-500000	USD
CY2018Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	400000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-100000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	800000	USD
CY2019Q1	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	25500000	USD
CY2019Q1	rtrx	Write Off Of Contingent Consideration WriteOffOfContingentConsideration	18000000.0	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	5619000	USD
CY2019Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3078000	USD
CY2018Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4689000	USD
CY2019Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2186000	USD
CY2018Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	930000	USD
CY2019Q3	us-gaap	Inventory Net InventoryNet	5264000	USD
CY2019Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	2400000	USD
CY2018Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1800000	USD
CY2019Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	16800000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	12700000	USD
CY2016Q2	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	500000	USD
CY2016Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	25000000.0	USD
CY2016	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-2300000	USD
CY2017	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-5700000	USD
CY2018	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1000000.0	USD
CY2019Q1	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-7500000	USD
CY2019Q3	us-gaap	Impairment Of Retained Interest ImpairmentOfRetainedInterest	15000000	USD

Files In Submission

Name	View Source	Status
0001438533-19-000036-index-headers.html	Edgar Link	pending
0001438533-19-000036-index.html	Edgar Link	pending
0001438533-19-000036.txt	Edgar Link	pending
0001438533-19-000036-xbrl.zip	Edgar Link	pending
ex09302019311.htm	Edgar Link	pending
ex09302019312.htm	Edgar Link	pending
ex09302019321.htm	Edgar Link	pending
ex09302019322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
productpipelineq319a02.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
rtrx-20190930.xsd	Edgar Link	pending
rtrx-20190930x10q.htm	Edgar Link	pending
rtrx-20190930x10q_htm.xml	Edgar Link	completed
rtrx-20190930_cal.xml	Edgar Link	unprocessable
rtrx-20190930_def.xml	Edgar Link	unprocessable
rtrx-20190930_lab.xml	Edgar Link	unprocessable
rtrx-20190930_pre.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TVTX
Travere Therapeutics Inc Stock $tvtx

2019 Q4 Form 10-Q Financial Statement

#000143853319000036 Filed on October 30, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TVTX Travere Therapeutics Inc Stock $tvtx

2019 Q4 Form 10-Q Financial Statement

#000143853319000036 Filed on October 30, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TVTX
Travere Therapeutics Inc Stock $tvtx